Core Viewpoint - Vison Pharma-B (02561) experienced a significant stock price increase, rising over 7% during trading and currently up 3.64% at HKD 31.88, driven by recent collaboration news with Anke Bio [1] Group 1: Company Developments - Anke Bio recently disclosed progress in its collaboration with Vison Pharma regarding the growth-promoting factor, Longpei, which is expected to receive approval soon [1] - On July 14, Anke Bio announced the signing of a strategic cooperation framework agreement with Vison Pharma to promote the market penetration of Longpei in China [1] - Vison Pharma's core product, Longpei, had its application for market approval accepted by the National Medical Products Administration of China in March 2024, with expectations for market launch in the second half of 2025 [1]
港股异动 维昇药业-B(02561)盘中涨超7% 公司核心产品隆培促生长素即将获批